LEO Pharma

The company aims to be a preferred partner for innovation in dermatology by addressing complex medical challenges and collaborating with partners to develop solutions that enhance patient care.

LEO Pharma’s activities at the annual meeting of the European Academy of Dermatology and Venereology, cover expert-led sessions, clinical cases, and real-world evidence designed to strengthen practice and advance outcomes for patients.

LEO Pharma Nordic operates in Denmark, Finland, Norway, and Sweden, with offices in Finland, Norway, and Sweden, employing about 25 people in sales, marketing, medical affairs, and market access.

LEO Pharma, founded in 1908, is an independent pharmaceutical company focused on research to improve dermatologists’ quality of care and patients’ lives globally, addressing conditions like psoriasis, atopic dermatitis, acne, and eczema.

The company offers career opportunities in various job positions.

LEO Pharma presents real-world efficacy data for its delgocitinib cream in treating **Chronic Hand Eczema (CHE) in adults**, based on findings shared at the **European Academy of Dermatology and Venereology (EADV) 2026**. The company also unveils **new clinical results for adolescent patients**, expanding the drug’s potential patient demographic. Delgocitinib, a topical JAK inhibitor, demonstrates outcomes in both adult and younger populations with moderate-to-severe CHE.

Oct 2026LEO Pharma GlobalNews article

LEO Pharma presents its largest scientific program at the **EADV 2026** dermatology congress in Vienna, running September 30–October 3. The event highlights the company’s expanded research in medical dermatology, targeting advancements in skin disease treatments. This marks the first time LEO Pharma will feature such an extensive lineup at the annual congress.

Sep 2026LEO Pharma GlobalNews article

LEO Pharma secures a positive opinion from the European Medicines Agency’s CHMP for **Anzupgo (delgocitinib) cream**, expanding its approval to treat **moderate-to-severe chronic hand eczema in adolescents** within the EU. The recommendation follows CHMP’s review of clinical data supporting the cream’s safety and efficacy for this patient group. LEO Pharma specializes in dermatological treatments and markets the product as a targeted therapy for inflammatory skin conditions.

Sep 2026LEO Pharma GlobalNews article

LEO Pharma secures FDA acceptance and **Priority Review** for its **dersimelagon** NDA, a potential treatment in dermatology. The company also finalizes its acquisition from **Tanabe Pharma**, expanding its portfolio of skin health therapies. The FDA’s Priority Review designation accelerates the review timeline for the drug candidate.

Sep 2026LEO Pharma GlobalNews article